Journal of Oncology / 2010 / Article / Tab 2

Clinical Study

Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer

Table 2

Best confirmed response in patients who received at least one complete cycle of chemotherapy (N = 44).

Best tumor responseNumber of patients%

 Partial response613.6
 Stable disease1840.9
 Progressive disease1534.1
 Unknown511.4